Seeking Answers About Transgender Heart Health

NORTHAMPTON, MA / ACCESSWIRE / March 23, 2023 / Abbott

Abbott

Chances are you know someone who's ended up in the emergency room for chest pain. Millions of people find themselves in this situation every year.

When people first arrive at the ER, doctors often run blood tests. The tests look for proteins in the bloodstream - referred to as biomarkers - that are released after the heart muscle has been damaged. The biomarkers help doctors diagnose heart attacks.

Two of the tests measure levels of two cardiac biomarkers in the blood: high-sensitivity cardiac troponin (hs-cTn) and N-terminal pro-brain natriuretic peptide (NT-proBNP).

Concentrations of these biomarkers are different in healthy men and women,^1,2 which helps clinicians determine whether they are considered elevated, a key element of diagnosing and determining a person's condition and whether they may have suffered a heart attack.

But what about transgender individuals, people who have a gender that is different than their sex assigned at birth? Which gender do the biomarkers reflect? Knowing this piece of information could help doctors better assess their biomarker levels.

A new study offers an important clue. The research indicates that the differences in the two biomarkers between healthy transgender women and transgender men were similar to those in healthy cisgender women and men. Cisgender individuals are people whose gender identity corresponds with the sex registered for them at birth. This suggests that sex hormones - not sex assigned at birth - drive the differences, an important revelation for clinical assessment.

The researchers measured the biomarkers using several tests, including Abbott's ARCHITECT STAT High-Sensitivity Troponin I test.

"This research presents essential new information about cardiac biomarkers in transgender individuals," said Alex Carterson, divisional vice president of medical, scientific and clinical affairs at Abbott. "Knowing more about the biomarkers in transgender people will allow doctors to better assess whether or not levels are elevated and will lead to better care."

The cardiac biomarkers hs-cTn and NT-proBNP are released into the bloodstream when the heart has been damaged. Cisgender males tend to have a higher natural concentration of hs-cTn than cisgender females,³ and cisgender females tend to have a higher natural concentration of NT-proBNP than cisgender males.⁴

Because there is an absence of medical literature that studies and defines cardiac biomarkers in transgender individuals, the team of researchers conducted a study to understand how hs-cTn and NT-proBNP concentrations differ between healthy cisgender individuals and healthy transgender individuals.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 112,20$, was eine Steigerung von +5,00% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

HSBC Trinkaus & Burkhardt GmbH

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer